[HTML][HTML] Classification of current anticancer immunotherapies
During the past decades, anticancer immunotherapy has evolved from a promising
therapeutic option to a robust clinical reality. Many immunotherapeutic regimens are now …
therapeutic option to a robust clinical reality. Many immunotherapeutic regimens are now …
[HTML][HTML] Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations
Autologous hematopoietic stem cell transplantation (aHSCT) is a well-established treatment
for malignancies such as multiple myeloma (MM) and lymphomas. Various changes in the …
for malignancies such as multiple myeloma (MM) and lymphomas. Various changes in the …
The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone
N Flomenberg, SM Devine, JF DiPersio, JL Liesveld… - Blood, 2005 - ashpublications.org
Hematopoietic progenitor cells (HPCs) traffic to and are retained in the marrow through the
trophic effects of the chemokine stromal cell-derived factor-1α (SDF-1α) binding to its …
trophic effects of the chemokine stromal cell-derived factor-1α (SDF-1α) binding to its …
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for …
Multiple myeloma is the most common indication for high-dose chemotherapy with
autologous stem cell support (ASCT) in North America today. Stem cell procurement for …
autologous stem cell support (ASCT) in North America today. Stem cell procurement for …
Proposed definition of 'poor mobilizer'in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo …
Many lymphoma and myeloma patients fail to undergo ASCT owing to poor mobilization.
Identification of poor mobilizers (PMs) would provide a tool for early intervention with new …
Identification of poor mobilizers (PMs) would provide a tool for early intervention with new …
Trial Watch: Chemotherapy with immunogenic cell death inducers
E Vacchelli, F Aranda, A Eggermont, J Galon… - …, 2014 - Taylor & Francis
Accumulating evidence suggests that the clinical efficacy of selected anticancer drugs,
including conventional chemotherapeutics as well as targeted anticancer agents, originates …
including conventional chemotherapeutics as well as targeted anticancer agents, originates …
Stem cell mobilization in multiple myeloma: challenges, strategies, and current developments
X Wei, Y Wei - Annals of Hematology, 2023 - Springer
Among hematological malignancies, multiple myeloma (MM) represents the leading
indication of autologous hematopoietic stem cell transplantation (auto-HCT). Auto-HCT is …
indication of autologous hematopoietic stem cell transplantation (auto-HCT). Auto-HCT is …
[HTML][HTML] Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic …
Collection of adequate hematopoietic stem cells (HSCs) is necessary for successful
autologous transplantation; however, a proportion of patients fail to collect the minimum …
autologous transplantation; however, a proportion of patients fail to collect the minimum …
Trial Watch—Immunostimulation with cytokines in cancer therapy
During the past decade, great efforts have been dedicated to the development of clinically
relevant interventions that would trigger potent (and hence potentially curative) anticancer …
relevant interventions that would trigger potent (and hence potentially curative) anticancer …
Advances in stem cell mobilization
IH Motabi, JF DiPersio - Blood reviews, 2012 - Elsevier
The use of mobilized peripheral blood stem cells (PBSCs) has largely replaced the use of
bone marrow as a source of stem cells for both allogeneic and autologous stem cell …
bone marrow as a source of stem cells for both allogeneic and autologous stem cell …